Circassia Pharmaceuticals
From Infogalactic: the planetary knowledge core
 |
|
| Public limited company | |
| Traded as | LSE: CIR |
| Industry | Pharmaceuticals |
| Founded | 2006 |
| Headquarters | Oxford, United Kingdom |
|
Key people
|
Francesco Granata, (Chairman) Steven Harris, (CEO) |
| Revenue | £10.8 million (2015)[1] |
| £(66.4) million (2015)[1] | |
| £(50.0) million (2015)[1] | |
| Website | www.circassia.co.uk |
Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
History
The company was founded by Steve Harris and Charles Swingland in 2006.[2] It was the subject of an Initial Public Offering in March 2014.[3]
Operations
The company's technology, ToleroMune, was initially developed by scientists at Imperial College London.[2] The company is in the process of developing a treatment for cat allergies.[4]
